Bilateral choroidal neovascularization after pegylated interferon therapy.
A 30-year-old male presented with gradual decrease in vision in his both eyes after the use of interferon alpha for his hepatitis-C. Ocular examination of patient included, Best Corrected Visual Acuity (BCVA), fundus photographs, Fundus Fluorescein Angiography (FFA) and Optical Coherence Tomography (OCT). His BCVA was recorded as 6/18 in the right eye and 6/12 in the left eye. The anterior segments were unremarkable, with normal intraocular Pressure (IOP) in his both eyes. Both fundi revealed the presence of bilateral Choroidal Neovascularization (CNV), confirmed on FFA and OCT. To the best of authors' knowledge, simultaneous presence of CNV in both eyes is not reported in the literature.
Department of Ophthalmology, The Aga Khan University Hospital, Karachi. / Department of Ophthalmology, Isra Postgraduate Institute of Ophthalmology, Karachi.
Pir Salim
PS
Mahar
Department of Ophthalmology, Isra Postgraduate Institute of Ophthalmology, Karachi.
Abdul Sami
AS
Memon
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000209:etiology; D005451:Fluorescein Angiography; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D058449:Intravitreal Injections; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068258:Bevacizumab; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a